Clinical Efficacy and Safety Analysis of Metformin Combined with Dapa-gliflozin in Patients with Type 2 Diabetes Mellitus Complicated with Heart Failure
Clinical Efficacy and Safety Analysis of Metformin Combined with Dapa-gliflozin in Patients with Type 2 Diabetes Mellitus Complicated with Heart Failure
Objective To analyze the efficacy and safety of metformin combined with dapagliflozin in patients with type 2 diabetes mellitus(T2DM)and heart failure(HF).Methods A total of ninety-six patients with T2DM combined with HF admitted to Dongping County Hospital of Traditional Chinese Medicine from November 2022 to November 2023 were selected as the study objects.They were divided into control group(n=48)and observation group(n=48)by random envelope method.Both groups received anti-heart failure treatment,the control group was selected metformin treatment,the observation group was selected metformin combined with dapagliflozin treatment.Blood glucose index,cardiac function index and occurrence of adverse reactions were compared between the two groups.Results After 3 months of treatment,compared with control group,fasting blood glucose,2-hour postprandial blood glucose,glycosyl-ated hemoglobin A1c level and N-terminal probrain natriuretic peptide level in observation group were lower,and left ventricular ejection fraction was higher,and the differences were statistically significant(all P<0.05).The total inci-dence of drug adverse reactions in the observation group was 6.25%,slightly higher than that in the control group(4.17%),but there was no statistically significant difference between groups(χ2=0.211,P>0.05).Conclusion For T2DM patients with HF,the combination of metformin and dapagliflozin can not only ensure good blood glucose con-trol,but also promote the improvement of cardiac function,and the drug safety performance is excellent.
关键词
2型糖尿病/二甲双胍/达格列净/用药安全性/心功能
Key words
Type 2 diabetes mellitus/Metformin/Dapagliflozin/Drug safety/Cardiac function
维普
万方数据